Banning DTC Rx ads will not lower drug prices, says US Budget Office
This article was originally published in Scrip
Executive Summary
Banning direct-to-consumer advertising for new prescription medicines in the US is unlikely to help reduce consumer spending on drugs and could result in drug makers changing their marketing strategy by spending more on promoting their products to physicians, the Congressional Budget Office has stated in an issue brief.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.